Abstract
Although antibody induction has gained in popularity, two agents are rarely combined. We retrospectively analyzed peripheral lymphocyte phenotypes of renal transplant recipients who received induction therapy with a different antibody/combination: alemtuzumab(C1H), Thymoglobulin(rATG), daclizumab(Dac), rATG. +. C1H, and rATG. +. Dac. CD4+ T-cells were suppressed by C1H and rATG. +. C1H, as well as by rATG and rATG. +. Dac but to a lesser extent. The effect lasted for 3. years at around 40% of baseline values. CD8+ T-cells showed a similar trend but had a more rapid recovery to baseline. CD19+ B-cells were effectively suppressed for 2. months by C1H and rATG. +. C1H, and abruptly returned to baseline afterwards; suppression by rATG(7 doses) was modest but lasted longer. A higher proportion of CD56. +. CD16+ Natural Killer cells in C1H treated patients suggested a relatively spared effect of C1H on this cell type. Low CD25+ T-cells by 5-dose Dac returned to baseline around 6. months, whereas rATG. +. C1H and rATG. +. Dac showed persistent effect. CD4. +. CD25hi T-cells were suppressed by both rATG. +. C1H and rATG. +. Dac, but the initial proportion of CD4. +. CD25hi T-cells among CD4+ T-cells and CD4. +. CD25hi/CD4. +. CD25lo ratio were significantly higher in rATG. +. C1H. Overall, with extensive and persistent lymphocyte suppression by a simple administration of agents, single-dose rATG. +. C1H induction can be an alternative in renal transplantation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 104-111 |
| Number of pages | 8 |
| Journal | Transplant Immunology |
| Volume | 25 |
| Issue number | 2-3 |
| DOIs | |
| State | Published - Sep 1 2011 |
| Externally published | Yes |
Fingerprint
Keywords
- Alemtuzumab
- Anti-thymocyte globulin
- Induction therapy
- Kidney transplantation
- Monoclonal antibody
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Transplantation
Cite this
Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation. / Sageshima, Junichiro; Ciancio, Gaetano; Guerra, Giselle; Gaynor, Jeffrey J.; Cova, Deborah; Zarak, Alberto; Chen, Linda; Mattiazzi, Adela; Kupin, Warren; Roth, David; Hanson, Lois; Livingstone, Alan S.; Ruiz, Phillip; Burke, George W.
In: Transplant Immunology, Vol. 25, No. 2-3, 01.09.2011, p. 104-111.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation
AU - Sageshima, Junichiro
AU - Ciancio, Gaetano
AU - Guerra, Giselle
AU - Gaynor, Jeffrey J.
AU - Cova, Deborah
AU - Zarak, Alberto
AU - Chen, Linda
AU - Mattiazzi, Adela
AU - Kupin, Warren
AU - Roth, David
AU - Hanson, Lois
AU - Livingstone, Alan S.
AU - Ruiz, Phillip
AU - Burke, George W.
PY - 2011/9/1
Y1 - 2011/9/1
N2 - Although antibody induction has gained in popularity, two agents are rarely combined. We retrospectively analyzed peripheral lymphocyte phenotypes of renal transplant recipients who received induction therapy with a different antibody/combination: alemtuzumab(C1H), Thymoglobulin(rATG), daclizumab(Dac), rATG. +. C1H, and rATG. +. Dac. CD4+ T-cells were suppressed by C1H and rATG. +. C1H, as well as by rATG and rATG. +. Dac but to a lesser extent. The effect lasted for 3. years at around 40% of baseline values. CD8+ T-cells showed a similar trend but had a more rapid recovery to baseline. CD19+ B-cells were effectively suppressed for 2. months by C1H and rATG. +. C1H, and abruptly returned to baseline afterwards; suppression by rATG(7 doses) was modest but lasted longer. A higher proportion of CD56. +. CD16+ Natural Killer cells in C1H treated patients suggested a relatively spared effect of C1H on this cell type. Low CD25+ T-cells by 5-dose Dac returned to baseline around 6. months, whereas rATG. +. C1H and rATG. +. Dac showed persistent effect. CD4. +. CD25hi T-cells were suppressed by both rATG. +. C1H and rATG. +. Dac, but the initial proportion of CD4. +. CD25hi T-cells among CD4+ T-cells and CD4. +. CD25hi/CD4. +. CD25lo ratio were significantly higher in rATG. +. C1H. Overall, with extensive and persistent lymphocyte suppression by a simple administration of agents, single-dose rATG. +. C1H induction can be an alternative in renal transplantation.
AB - Although antibody induction has gained in popularity, two agents are rarely combined. We retrospectively analyzed peripheral lymphocyte phenotypes of renal transplant recipients who received induction therapy with a different antibody/combination: alemtuzumab(C1H), Thymoglobulin(rATG), daclizumab(Dac), rATG. +. C1H, and rATG. +. Dac. CD4+ T-cells were suppressed by C1H and rATG. +. C1H, as well as by rATG and rATG. +. Dac but to a lesser extent. The effect lasted for 3. years at around 40% of baseline values. CD8+ T-cells showed a similar trend but had a more rapid recovery to baseline. CD19+ B-cells were effectively suppressed for 2. months by C1H and rATG. +. C1H, and abruptly returned to baseline afterwards; suppression by rATG(7 doses) was modest but lasted longer. A higher proportion of CD56. +. CD16+ Natural Killer cells in C1H treated patients suggested a relatively spared effect of C1H on this cell type. Low CD25+ T-cells by 5-dose Dac returned to baseline around 6. months, whereas rATG. +. C1H and rATG. +. Dac showed persistent effect. CD4. +. CD25hi T-cells were suppressed by both rATG. +. C1H and rATG. +. Dac, but the initial proportion of CD4. +. CD25hi T-cells among CD4+ T-cells and CD4. +. CD25hi/CD4. +. CD25lo ratio were significantly higher in rATG. +. C1H. Overall, with extensive and persistent lymphocyte suppression by a simple administration of agents, single-dose rATG. +. C1H induction can be an alternative in renal transplantation.
KW - Alemtuzumab
KW - Anti-thymocyte globulin
KW - Induction therapy
KW - Kidney transplantation
KW - Monoclonal antibody
UR - http://www.scopus.com/inward/record.url?scp=80052338014&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052338014&partnerID=8YFLogxK
U2 - 10.1016/j.trim.2011.07.002
DO - 10.1016/j.trim.2011.07.002
M3 - Article
C2 - 21784152
AN - SCOPUS:80052338014
VL - 25
SP - 104
EP - 111
JO - Transplant Immunology
JF - Transplant Immunology
SN - 0966-3274
IS - 2-3
ER -